Format

Send to

Choose Destination
Cancers (Basel). 2018 Mar 28;10(4). pii: E93. doi: 10.3390/cancers10040093.

The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Author information

1
Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria. Ines.Garces@lbicr.lbg.ac.at.
2
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria. Ines.Garces@lbicr.lbg.ac.at.
3
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria. Ines.Garces@lbicr.lbg.ac.at.
4
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria. huan-chang.liang@meduniwien.ac.at.
5
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB21QP, UK. sdt36@cam.ac.uk.
6
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria. Sabine.Lagger@vetmeduni.ac.at.
7
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria. Olaf.merkel@meduniwien.ac.at.
8
Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria. Lukas.Kenner@meduniwien.ac.at.
9
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria. Lukas.Kenner@meduniwien.ac.at.
10
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria. Lukas.Kenner@meduniwien.ac.at.

Abstract

The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles. However, as a result of the increasing knowledge of the role of AP-1 TFs in disease, these TFs are being recognized as promising therapeutic targets for various malignancies. In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.

KEYWORDS:

Activator Protein-1 (AP-1); Anaplastic Large Cell Lymphoma (ALCL); CD-30; Classical Hodgkin Lymphoma (CHL); Peripheral T-cell Lymphoma (PTCL); Transcription Factors (TFs)

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center